Bearstar Strategies

Ownership

Private

Employees

~10

Therapeutic Areas

Hematology

Stage

Phase 1

Modalities

Bispecific antibody

Bearstar Strategies General Information

Developing T cell engaging therapeutics for hematologic malignancies

Contact Information

Website

Primary Industry

Consulting

Corporate Office

Drug Pipeline

AMV564

Phase 1

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to Bearstar Strategies's pipeline data

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Bearstar Strategies Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view Bearstar Strategies's complete valuation and funding history, request access »